SGCB and benign neoplasm: The bioregulatory activity of NO is similar in benign tumours and in normal kidney, whereas there is a shift of NO signalling in high-grade malignant tumours, with a loss of endogeneous NO synthesis, but the maintenance of sGC, the receptor for exogeneous NO.